ArticleCancer cell international2025
THOC1 binds to U2AF2 and regulates ovarian cancer progression through the beta-catenin / c-myc / cyclinD1 signaling pathway.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundOvarian cancer (OV) poses a significant challenge in oncology due to its complex molecular mechanisms and poor prognosis. This study aims to identify key genes associated with OV progression and explore their potential as therapeutic targets.
methodsUsing multiple machine learning models to identify a key gene in OV. Pan-cancer analysis was conducted to evaluate the expression, mutation, diagnosis, prognosis and pathway of THOC1 across various tumors. Cell proliferation, migration, and invasion experiments were performed to assess the role of THOC1 in OV. Immunoprecipitation (IP), GST pull-down, immunofluorescence, and reverse transcription polymerase chain reaction (RT-qPCR) were employed to identify THOC1-interacting proteins. Finally, RNA sequencing and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were utilized to investigate the molecular pathways involving THOC1 and its interaction with U2 Small Nuclear RNA Auxiliary Factor 2 (U2AF2).
resultsTHOC1 plays an important diagnostic and prognostic role in a variety of tumors and is involved in multiple cancer pathways. Functional assays demonstrated that THOC1 suppresses OV cell proliferation, migration, and invasion. Mechanistically, THOC1 directly binds to U2AF2, with THOC1-340S being a critical interaction site. THOC1 regulates U2AF2 expression, which mediates the suppression of OV progression. RNA-seq and KEGG pathway analysis revealed that THOC1 inhibits the Wnt signaling pathway through its interaction with U2AF2, as evidenced by changes in the protein levels of cyclinD1, c-myc, and beta-catenin.
conclusionsThis study highlights the pivotal role of THOC1 in OV progression and identifies the THOC1-U2AF2 axis as a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.